Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer.
Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase ½ clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is ongoing IND-enabling studies.
The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 9, 24 | 0.00 Increased by +100.00% | -0.64 Increased by +100.00% |
| Feb 27, 24 | -0.62 Decreased by -26.53% | -0.60 Decreased by -3.33% |
| Nov 14, 23 | -0.59 Decreased by -43.90% | -0.58 Decreased by -1.72% |
| Aug 10, 23 | -0.51 Decreased by -34.21% | -0.53 Increased by +3.77% |
| May 11, 23 | -0.44 Decreased by -22.22% | -0.51 Increased by +13.73% |
| Mar 16, 23 | -0.49 Decreased by -36.11% | -0.43 Decreased by -13.95% |
| Nov 10, 22 | -0.41 Decreased by -5.13% | -0.44 Increased by +6.82% |
| Aug 10, 22 | -0.38 Increased by +88.01% | -0.41 Increased by +7.32% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0.00 Decreased by N/A% | -33.65 M Decreased by -76.67% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -29.09 M Decreased by -59.84% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -20.17 M Decreased by -15.88% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Increased by +100.00% | -19.77 M Decreased by -14.36% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -19.04 M Decreased by -53.26% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -18.20 M Decreased by -84.99% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -17.41 M Decreased by -156.60% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | -2.43 M Decreased by N/A% | -17.29 M Decreased by -162.75% | Increased by +710.90% Decreased by N/A% |